Clostridium difficile Infections - Pipeline Review, H1 2017
Clostridium difficile Infections - Pipeline Review, H1 2017
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.
Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 11, 29, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively.
Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.
Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 11, 29, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively.
Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
Absynth Biologics Ltd
Actelion Ltd
AIMM Therapeutics BV
Akthelia Pharmaceuticals Ltd
AmpliPhi Biosciences Corp
Appili Therapeutics
Assembly Biosciences Inc
AvidBiotics Corp
C3J Therapeutics Inc
CaroGen Corp
Crestone Inc
Da Volterra SAS
Daiichi Sankyo Company Ltd
Evec Inc
GangaGen Inc
ImmunoBiology Ltd
Immuron Ltd
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
Merck & Co Inc
MGB Biopharma Ltd
Microbiotix Inc
Micropharm Ltd
Miyarisan Pharmaceutical Company Ltd
Nabriva Therapeutics AG
Nanotherapeutics Inc
Novabiotics Ltd
NovoBiotic Pharmaceuticals LLC
Oragenics Inc
Otsuka Holdings Co Ltd
Pfizer Inc
Prokarium Ltd
Rebiotix Inc
Sanofi Pasteur SA
Second Genome Inc
Seres Therapeutics Inc
Serometrix LLC
Sorrento Therapeutics Inc
Summit Therapeutics Plc
Synthetic Biologics Inc
Valevia UK Ltd
Valneva SE
XBiotech Inc
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles
ABCD-01 - Drug Profile
ABIM-101 - Drug Profile
AKT-10081 - Drug Profile
Antibodies for Enterocolitis - Drug Profile
Antibodies to Inhibit Toxin A and Toxin B for Clostridium difficile Infections - Drug Profile
AvR2-V10 - Drug Profile
Biologic for Clostridium difficile Infections - Drug Profile
Biologics for Clostridium Difficile Infections - Drug Profile
cadazolid - Drug Profile
CBM-588 - Drug Profile
CD-17DL - Drug Profile
Cdiff Snare - Drug Profile
clofazimine - Drug Profile
Clostridium difficile (virus like particle) vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
CP-101 - Drug Profile
CRS-3123 - Drug Profile
DAV-132 - Drug Profile
DiffiKil - Drug Profile
Drugs for Clostridium difficile Infections - Drug Profile
DS-2969 - Drug Profile
EV-029104 - Drug Profile
EV-029105A - Drug Profile
fidaxomicin - Drug Profile
FIN-403 - Drug Profile
IMM-529 - Drug Profile
INS-5010 - Drug Profile
MBX-500 - Drug Profile
MCB-3681 - Drug Profile
MCB-3837 - Drug Profile
metronidazole - Drug Profile
MGBBP-3 - Drug Profile
Monoclonal Antibodies for Clostridium difficile Infections - Drug Profile
Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections - Drug Profile
Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile
Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile
Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
NP-432 - Drug Profile
OG-253 - Drug Profile
OG-716 - Drug Profile
OPS-2071 - Drug Profile
OraCAb - Drug Profile
P-100031 - Drug Profile
P-4A - Drug Profile
PF-06425090 - Drug Profile
PolyCAb - Drug Profile
Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile
ramoplanin - Drug Profile
RBX-2660 - Drug Profile
RBX-7455 - Drug Profile
ribaxamase - Drug Profile
ridinilazole - Drug Profile
SER-109 - Drug Profile
SER-262 - Drug Profile
SHP-01 - Drug Profile
Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile
Small Molecules for Clostridium Difficile Infections - Drug Profile
Small Molecules for Clostridium Difficile Infections - Drug Profile
Small Molecules for Clostridium difficile Infections - Drug Profile
Small Molecules to Inhibit 23S rRNA for Clostridium difficile and Helicobacter pylori Infections - Drug Profile
Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile
Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile
Small Molecules to Inhibit Metalloprotease for Clostridium difficile Infections - Drug Profile
Small Molecules to Inhibit Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
SQ-641 - Drug Profile
SYN-006 - Drug Profile
SYN-007 - Drug Profile
TNP-2092 - Drug Profile
VAL-301 - Drug Profile
VE-303 - Drug Profile
VLA-84 - Drug Profile
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
Absynth Biologics Ltd
Actelion Ltd
AIMM Therapeutics BV
Akthelia Pharmaceuticals Ltd
AmpliPhi Biosciences Corp
Appili Therapeutics
Assembly Biosciences Inc
AvidBiotics Corp
C3J Therapeutics Inc
CaroGen Corp
Crestone Inc
Da Volterra SAS
Daiichi Sankyo Company Ltd
Evec Inc
GangaGen Inc
ImmunoBiology Ltd
Immuron Ltd
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
Merck & Co Inc
MGB Biopharma Ltd
Microbiotix Inc
Micropharm Ltd
Miyarisan Pharmaceutical Company Ltd
Nabriva Therapeutics AG
Nanotherapeutics Inc
Novabiotics Ltd
NovoBiotic Pharmaceuticals LLC
Oragenics Inc
Otsuka Holdings Co Ltd
Pfizer Inc
Prokarium Ltd
Rebiotix Inc
Sanofi Pasteur SA
Second Genome Inc
Seres Therapeutics Inc
Serometrix LLC
Sorrento Therapeutics Inc
Summit Therapeutics Plc
Synthetic Biologics Inc
Valevia UK Ltd
Valneva SE
XBiotech Inc
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles
ABCD-01 - Drug Profile
ABIM-101 - Drug Profile
AKT-10081 - Drug Profile
Antibodies for Enterocolitis - Drug Profile
Antibodies to Inhibit Toxin A and Toxin B for Clostridium difficile Infections - Drug Profile
AvR2-V10 - Drug Profile
Biologic for Clostridium difficile Infections - Drug Profile
Biologics for Clostridium Difficile Infections - Drug Profile
cadazolid - Drug Profile
CBM-588 - Drug Profile
CD-17DL - Drug Profile
Cdiff Snare - Drug Profile
clofazimine - Drug Profile
Clostridium difficile (virus like particle) vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
Clostridium difficile vaccine - Drug Profile
CP-101 - Drug Profile
CRS-3123 - Drug Profile
DAV-132 - Drug Profile
DiffiKil - Drug Profile
Drugs for Clostridium difficile Infections - Drug Profile
DS-2969 - Drug Profile
EV-029104 - Drug Profile
EV-029105A - Drug Profile
fidaxomicin - Drug Profile
FIN-403 - Drug Profile
IMM-529 - Drug Profile
INS-5010 - Drug Profile
MBX-500 - Drug Profile
MCB-3681 - Drug Profile
MCB-3837 - Drug Profile
metronidazole - Drug Profile
MGBBP-3 - Drug Profile
Monoclonal Antibodies for Clostridium difficile Infections - Drug Profile
Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections - Drug Profile
Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile
Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile
Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
NP-432 - Drug Profile
OG-253 - Drug Profile
OG-716 - Drug Profile
OPS-2071 - Drug Profile
OraCAb - Drug Profile
P-100031 - Drug Profile
P-4A - Drug Profile
PF-06425090 - Drug Profile
PolyCAb - Drug Profile
Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile
ramoplanin - Drug Profile
RBX-2660 - Drug Profile
RBX-7455 - Drug Profile
ribaxamase - Drug Profile
ridinilazole - Drug Profile
SER-109 - Drug Profile
SER-262 - Drug Profile
SHP-01 - Drug Profile
Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile
Small Molecules for Clostridium Difficile Infections - Drug Profile
Small Molecules for Clostridium Difficile Infections - Drug Profile
Small Molecules for Clostridium difficile Infections - Drug Profile
Small Molecules to Inhibit 23S rRNA for Clostridium difficile and Helicobacter pylori Infections - Drug Profile
Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile
Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile
Small Molecules to Inhibit Metalloprotease for Clostridium difficile Infections - Drug Profile
Small Molecules to Inhibit Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile
SQ-641 - Drug Profile
SYN-006 - Drug Profile
SYN-007 - Drug Profile
TNP-2092 - Drug Profile
VAL-301 - Drug Profile
VE-303 - Drug Profile
VLA-84 - Drug Profile
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics BV, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corp, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3J Therapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corp, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra SAS, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nabriva Therapeutics AG, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Second Genome Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Serometrix LLC, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by XBiotech Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H1 2017
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics BV, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corp, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3J Therapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corp, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra SAS, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nabriva Therapeutics AG, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Second Genome Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Serometrix LLC, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Ltd, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by XBiotech Inc, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H1 2017
LIST OF FIGURES
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
COMPANIES MENTIONED
Absynth Biologics Ltd
Actelion Ltd
AIMM Therapeutics BV
Akthelia Pharmaceuticals Ltd
AmpliPhi Biosciences Corp
Appili Therapeutics
Assembly Biosciences Inc
AvidBiotics Corp
C3J Therapeutics Inc
CaroGen Corp
Crestone Inc
Da Volterra SAS
Daiichi Sankyo Company Ltd
Evec Inc
GangaGen Inc
ImmunoBiology Ltd
Immuron Ltd
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
Merck & Co Inc
MGB Biopharma Ltd
Microbiotix Inc
Micropharm Ltd
Miyarisan Pharmaceutical Company Ltd
Nabriva Therapeutics AG
Nanotherapeutics Inc
Novabiotics Ltd
NovoBiotic Pharmaceuticals LLC
Oragenics Inc
Otsuka Holdings Co Ltd
Pfizer Inc
Prokarium Ltd
Rebiotix Inc
Sanofi Pasteur SA
Second Genome Inc
Seres Therapeutics Inc
Serometrix LLC
Sorrento Therapeutics Inc
Summit Therapeutics Plc
Synthetic Biologics Inc
Valevia UK Ltd
Valneva SE
XBiotech Inc
Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
COMPANIES MENTIONED
Absynth Biologics Ltd
Actelion Ltd
AIMM Therapeutics BV
Akthelia Pharmaceuticals Ltd
AmpliPhi Biosciences Corp
Appili Therapeutics
Assembly Biosciences Inc
AvidBiotics Corp
C3J Therapeutics Inc
CaroGen Corp
Crestone Inc
Da Volterra SAS
Daiichi Sankyo Company Ltd
Evec Inc
GangaGen Inc
ImmunoBiology Ltd
Immuron Ltd
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
Merck & Co Inc
MGB Biopharma Ltd
Microbiotix Inc
Micropharm Ltd
Miyarisan Pharmaceutical Company Ltd
Nabriva Therapeutics AG
Nanotherapeutics Inc
Novabiotics Ltd
NovoBiotic Pharmaceuticals LLC
Oragenics Inc
Otsuka Holdings Co Ltd
Pfizer Inc
Prokarium Ltd
Rebiotix Inc
Sanofi Pasteur SA
Second Genome Inc
Seres Therapeutics Inc
Serometrix LLC
Sorrento Therapeutics Inc
Summit Therapeutics Plc
Synthetic Biologics Inc
Valevia UK Ltd
Valneva SE
XBiotech Inc
